External-beam radiotherapy is an effective bridging therapy for patients with liver cancer who are awaiting transplant, but it is rarely used compared to other liver-directed therapies.
Many hospitals require people with alcohol-related liver disease to complete a period of sobriety before they can be added to the waiting list for a liver. But this thinking may be changing.
Mirum Pharmaceuticals said its drug became the first US-approved therapy for treating itching in patients with rare liver disorder Alagille syndrome and would be available for distribution immediately.